ArticleDiabetes, obesity & metabolism2026
Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy-Based Cross-Sectional Survey.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy-Based Cross-Sectional Survey.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimsUsers of semaglutide for weight management (SEMA-WM) may not follow the recommended treatment regimen. We investigated SEMA-WM treatment patterns among Danish adult users.
methodsA questionnaire-based survey was conducted across 28 Danish community pharmacies between March and May 2025. Adults redeeming a SEMA-WM prescription were invited to participate, with first-time users invited to a follow-up survey after 6 months.
resultsOf 1470 individuals invited, 767 (52%) completed the questionnaire. Forty-five percent used 1 mg as their current dose, and 8% expected to reach 2.4 mg. Ten percent reported dosing SEMA-WM by "counting clicks" on the injection pen, in contrast with official prescribing guidelines. Users treated for 1-3 months reported a median weight loss of 6% (IQR 3-7), increasing to 12% (IQR 9-14), 17% (IQR 12-21), and 20% (IQR 15-26) for those treated for 3-6 months, 6-12 months, and > 1 year, respectively. Weight loss by treatment duration was similar among 1 mg users. Twenty-four percent reported reduced/discontinued concomitant medication use following SEMA-WM initiation, especially for muscle/joint pain (30%) and antihypertensives (24%). Reduced/discontinued medication use was similar among 1 mg users. Among 42 first-time users, 83% were still using SEMA-WM after 6 months, usually 1 mg (60%). Among users who had discontinued treatment (17%), side effects were the most reported reason.
conclusionsMany SEMA-WM users remained on 1 mg and reported weight loss and medication reductions similar to the overall cohort. Findings indicate that some users appear to obtain the desired effect at 1 mg, underscoring the need for better guidance on individualized treatment trajectories.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.